Form 4: Seres Therapeutics Executive Sells Shares to Cover Taxes After RSU Vesting

Matthew R. Henn, Chief Scientific Officer and EVP of Seres Therapeutics, sold shares of common stock on August 16, 2024, to cover taxes related to the vesting of restricted stock units.

Summary

• Matthew R. Henn, a reporting person and Chief Scientific Officer and EVP at Seres Therapeutics, Inc., filed a Form 4.
• On August 15, 2024, Henn acquired 2,813 shares of common stock through the vesting of restricted stock units.
• On August 16, 2024, Henn sold 923 shares of common stock at a weighted average price of $0.84 per share.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on April 13, 2023, to cover taxes associated with the vesting of the restricted stock units.
• Following the reported transactions, Henn beneficially owns 67,247 shares of Seres Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction appears to be a routine sale of shares to cover tax obligations related to vested RSUs, executed under a pre-arranged trading plan.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It indicates that a company executive is selling shares, likely to cover tax obligations arising from the vesting of restricted stock units. Such transactions are common and do not necessarily reflect a negative outlook on the company's future prospects.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, although it is likely to be minimal given the context of tax obligations and the pre-arranged trading plan.

Key Dates